EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS IN TREATMENT OF NON-SMALL CELL LUNG CANCER
NOBEL MEDICUS, vol.14, no.3, pp.5-8, 2018 (ESCI, Scopus)
- Publication Type: Article / Article
- Volume: 14 Issue: 3
- Publication Date: 2018
- Journal Name: NOBEL MEDICUS
- Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus
- Page Numbers: pp.5-8
- Hacettepe University Affiliated: Yes
Abstract
Mutation of epidermal growth factor receptor (EGFR) is one of the targeted mutations in treatment of non-small cell lung cancer (NSCLC). Mutation of EGFR occurs in 15-40% of all patients with NSCLC. In this review, efficacy of different EGFR inhibitors used in NSCLC treatment is evaluated.